JP2016074725A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016074725A5 JP2016074725A5 JP2015238622A JP2015238622A JP2016074725A5 JP 2016074725 A5 JP2016074725 A5 JP 2016074725A5 JP 2015238622 A JP2015238622 A JP 2015238622A JP 2015238622 A JP2015238622 A JP 2015238622A JP 2016074725 A5 JP2016074725 A5 JP 2016074725A5
- Authority
- JP
- Japan
- Prior art keywords
- gallate
- cis
- trans
- composition
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 gallate ester Chemical class 0.000 claims 104
- 239000000203 mixture Substances 0.000 claims 45
- LNTHITQWFMADLM-UHFFFAOYSA-N Gallic acid Natural products OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims 38
- LNTHITQWFMADLM-UHFFFAOYSA-M gallate Chemical compound OC1=CC(C([O-])=O)=CC(O)=C1O LNTHITQWFMADLM-UHFFFAOYSA-M 0.000 claims 30
- 201000010099 disease Diseases 0.000 claims 25
- 229940074391 Gallic acid Drugs 0.000 claims 23
- 235000004515 gallic acid Nutrition 0.000 claims 23
- VFPFQHQNJCMNBZ-UHFFFAOYSA-N Ethyl gallate Chemical compound CCOC(=O)C1=CC(O)=C(O)C(O)=C1 VFPFQHQNJCMNBZ-UHFFFAOYSA-N 0.000 claims 10
- IPMYMEWFZKHGAX-ZKSIBHASSA-N Theaflavin Natural products C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 claims 10
- TYCUSKFOGZNIBO-UHFFFAOYSA-N hexadecyl 3,4,5-trihydroxybenzoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 TYCUSKFOGZNIBO-UHFFFAOYSA-N 0.000 claims 10
- RPWFJAMTCNSJKK-UHFFFAOYSA-N Dodecyl gallate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 RPWFJAMTCNSJKK-UHFFFAOYSA-N 0.000 claims 9
- 229940081973 S-Adenosylmethionine Drugs 0.000 claims 9
- MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine zwitterion Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 claims 9
- 229960001570 ademetionine Drugs 0.000 claims 9
- 235000010386 dodecyl gallate Nutrition 0.000 claims 9
- YBMTWYWCLVMFFD-UHFFFAOYSA-N 3-methylbutyl 3,4,5-trihydroxybenzoate Chemical compound CC(C)CCOC(=O)C1=CC(O)=C(O)C(O)=C1 YBMTWYWCLVMFFD-UHFFFAOYSA-N 0.000 claims 6
- 229940075579 Propyl Gallate Drugs 0.000 claims 6
- 206010037175 Psychiatric disease Diseases 0.000 claims 6
- 200000000018 inflammatory disease Diseases 0.000 claims 6
- 201000009673 liver disease Diseases 0.000 claims 6
- ZTHYODDOHIVTJV-UHFFFAOYSA-N propyl 3,4,5-trihydroxybenzoate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims 6
- 235000010388 propyl gallate Nutrition 0.000 claims 6
- 239000000473 propyl gallate Substances 0.000 claims 6
- NNCBVVNCQYNPPB-UHFFFAOYSA-N 2-hydroxyethyl 3,4,5-trihydroxybenzoate Chemical compound OCCOC(=O)C1=CC(O)=C(O)C(O)=C1 NNCBVVNCQYNPPB-UHFFFAOYSA-N 0.000 claims 5
- UCLHVCFKZSLALE-UHFFFAOYSA-N 2-methylpropyl 3,4,5-trihydroxybenzoate Chemical compound CC(C)COC(=O)C1=CC(O)=C(O)C(O)=C1 UCLHVCFKZSLALE-UHFFFAOYSA-N 0.000 claims 5
- 239000004262 Ethyl gallate Substances 0.000 claims 5
- FJYGFTHLNNSVPY-BBXLVSEPSA-N Theaflavin digallate Chemical compound C1=C([C@@H]2[C@@H](CC3=C(O)C=C(O)C=C3O2)O)C=C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(=O)C2=C1C([C@H]1OC3=CC(O)=CC(O)=C3C[C@H]1O)=CC(O)=C2OC(=O)C1=CC(O)=C(O)C(O)=C1 FJYGFTHLNNSVPY-BBXLVSEPSA-N 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 235000019277 ethyl gallate Nutrition 0.000 claims 5
- CMACDBPSYMYMKZ-UHFFFAOYSA-N heptyl 3,4,5-trihydroxybenzoate Chemical compound CCCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 CMACDBPSYMYMKZ-UHFFFAOYSA-N 0.000 claims 5
- DQHJNOHLEKVUHU-UHFFFAOYSA-N hexyl 3,4,5-trihydroxybenzoate Chemical compound CCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 DQHJNOHLEKVUHU-UHFFFAOYSA-N 0.000 claims 5
- 125000005644 linolenyl group Chemical group 0.000 claims 5
- 125000005645 linoleyl group Chemical group 0.000 claims 5
- KSNJEADFLJNDCP-UHFFFAOYSA-N nonyl 3,4,5-trihydroxybenzoate Chemical compound CCCCCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 KSNJEADFLJNDCP-UHFFFAOYSA-N 0.000 claims 5
- BRNPAEUKZMBRLQ-UHFFFAOYSA-N octadecyl 3,4,5-trihydroxybenzoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 BRNPAEUKZMBRLQ-UHFFFAOYSA-N 0.000 claims 5
- 235000010387 octyl gallate Nutrition 0.000 claims 5
- 239000000574 octyl gallate Substances 0.000 claims 5
- NRPKURNSADTHLJ-UHFFFAOYSA-N octyl gallate Chemical compound CCCCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 NRPKURNSADTHLJ-UHFFFAOYSA-N 0.000 claims 5
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 5
- IIOADSXXVWNOSC-UHFFFAOYSA-N pentyl 3,4,5-trihydroxybenzoate Chemical compound CCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 IIOADSXXVWNOSC-UHFFFAOYSA-N 0.000 claims 5
- TXGSOSAONMOPDL-UHFFFAOYSA-N propan-2-yl 3,4,5-trihydroxybenzoate Chemical compound CC(C)OC(=O)C1=CC(O)=C(O)C(O)=C1 TXGSOSAONMOPDL-UHFFFAOYSA-N 0.000 claims 5
- 235000014620 theaflavin Nutrition 0.000 claims 5
- WODIFPGOPHHDSJ-UHFFFAOYSA-N undecyl 3,4,5-trihydroxybenzoate Chemical compound CCCCCCCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 WODIFPGOPHHDSJ-UHFFFAOYSA-N 0.000 claims 5
- MTPIQEWGULCIPM-UHFFFAOYSA-N 2-ethylhexyl 3,4,5-trihydroxybenzoate Chemical compound CCCCC(CC)COC(=O)C1=CC(O)=C(O)C(O)=C1 MTPIQEWGULCIPM-UHFFFAOYSA-N 0.000 claims 4
- 206010003816 Autoimmune disease Diseases 0.000 claims 4
- 208000008665 Gastrointestinal Disease Diseases 0.000 claims 4
- 208000009883 Joint Disease Diseases 0.000 claims 4
- 208000009625 Lesch-Nyhan Syndrome Diseases 0.000 claims 4
- 208000009025 Nervous System Disease Diseases 0.000 claims 4
- FEPAFOYQTIEEIS-IZUGRSKYSA-N [(2R,3R,4R)-3,4,5-trihydroxy-4-[(3,4,5-trihydroxybenzoyl)oxymethyl]oxolan-2-yl]methyl 3,4,5-trihydroxybenzoate Chemical compound C([C@H]1OC([C@@]([C@@H]1O)(O)COC(=O)C=1C=C(O)C(O)=C(O)C=1)O)OC(=O)C1=CC(O)=C(O)C(O)=C1 FEPAFOYQTIEEIS-IZUGRSKYSA-N 0.000 claims 4
- SMZJCCHIPATQCN-LUTQBAROSA-N [(2R,3R,4S,5R)-2,3,4,5-tetrahydroxy-6-oxohexyl] 3,4,5-trihydroxybenzoate Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COC(=O)C1=CC(O)=C(O)C(O)=C1 SMZJCCHIPATQCN-LUTQBAROSA-N 0.000 claims 4
- AOTRKUOCGUXQCY-UHFFFAOYSA-N decyl 3,4,5-trihydroxybenzoate Chemical compound CCCCCCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 AOTRKUOCGUXQCY-UHFFFAOYSA-N 0.000 claims 4
- 239000000555 dodecyl gallate Substances 0.000 claims 4
- 229940080643 dodecyl gallate Drugs 0.000 claims 4
- GJCYPSBOSGWHEO-UHFFFAOYSA-N 6-methylheptyl 3,4,5-trihydroxybenzoate Chemical compound CC(C)CCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 GJCYPSBOSGWHEO-UHFFFAOYSA-N 0.000 claims 3
- 210000003169 Central Nervous System Anatomy 0.000 claims 3
- 206010012378 Depression Diseases 0.000 claims 3
- 206010061366 Soft tissue disease Diseases 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- 239000002775 capsule Substances 0.000 claims 3
- 150000002500 ions Chemical class 0.000 claims 3
- 206010001627 Alcoholic liver disease Diseases 0.000 claims 2
- 206010003246 Arthritis Diseases 0.000 claims 2
- COVFEVWNJUOYRL-UHFFFAOYSA-M Digallic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C([O-])=O)O)=C1 COVFEVWNJUOYRL-UHFFFAOYSA-M 0.000 claims 2
- 102100016790 HPRT1 Human genes 0.000 claims 2
- 101710011940 HPRT1 Proteins 0.000 claims 2
- 230000036917 MEAN CMAX Effects 0.000 claims 2
- 206010057840 Major depression Diseases 0.000 claims 2
- 206010061536 Parkinson's disease Diseases 0.000 claims 2
- 230000036823 Plasma Levels Effects 0.000 claims 2
- 206010039775 Seasonal affective disease Diseases 0.000 claims 2
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims 2
- 206010057589 Total hypoxanthine-guanine phosphoribosyl transferase deficiency Diseases 0.000 claims 2
- 208000007979 Treatment-Resistant Depressive Disorder Diseases 0.000 claims 2
- ARVSLJYYYOTWNA-UHFFFAOYSA-N [2,3-dihydroxy-5-[2-[2-(2-methoxyethoxy)ethoxy]ethoxycarbonyl]phenyl] 3,4,5-trihydroxybenzoate Chemical compound COCCOCCOCCOC(=O)C1=CC(O)=C(O)C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)=C1 ARVSLJYYYOTWNA-UHFFFAOYSA-N 0.000 claims 2
- 201000008804 arthropathy Diseases 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 200000000011 liver disorder Diseases 0.000 claims 2
- 230000000926 neurological Effects 0.000 claims 2
- 235000003715 nutritional status Nutrition 0.000 claims 2
- 230000003647 oxidation Effects 0.000 claims 2
- 238000007254 oxidation reaction Methods 0.000 claims 2
- 230000000275 pharmacokinetic Effects 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- 231100000486 side effect Toxicity 0.000 claims 2
- BQWQGCZOPQEUIQ-UHFFFAOYSA-N tetradecyl 3,4,5-trihydroxybenzoate Chemical compound CCCCCCCCCCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 BQWQGCZOPQEUIQ-UHFFFAOYSA-N 0.000 claims 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical group O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims 1
- 230000035533 AUC Effects 0.000 claims 1
- 206010001897 Alzheimer's disease Diseases 0.000 claims 1
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 206010057666 Anxiety disease Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000006673 Asthma Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 230000036912 Bioavailability Effects 0.000 claims 1
- 206010004938 Bipolar disease Diseases 0.000 claims 1
- 208000008787 Cardiovascular Disease Diseases 0.000 claims 1
- 206010008635 Cholestasis Diseases 0.000 claims 1
- 230000037242 Cmax Effects 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000010247 Contact Dermatitis Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012401 Depressive disease Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010072268 Drug-induced liver injury Diseases 0.000 claims 1
- 206010013982 Dysthymic disease Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010017758 Gastric cancer Diseases 0.000 claims 1
- 208000002488 Headache Disorders Diseases 0.000 claims 1
- 206010019641 Hepatic cirrhosis Diseases 0.000 claims 1
- 206010019799 Hepatitis viral Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010025135 Lupus erythematosus Diseases 0.000 claims 1
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 1
- 208000008338 Non-alcoholic Fatty Liver Disease Diseases 0.000 claims 1
- 108009000135 Nonalcoholic fatty liver disease Proteins 0.000 claims 1
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061920 Psychotic disease Diseases 0.000 claims 1
- 206010038038 Rectal cancer Diseases 0.000 claims 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010040490 Sexually transmitted disease Diseases 0.000 claims 1
- 206010040984 Sleep disease Diseases 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 201000001320 atherosclerosis Diseases 0.000 claims 1
- 201000003084 atypical depressive disease Diseases 0.000 claims 1
- 230000035514 bioavailability Effects 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 230000001721 combination Effects 0.000 claims 1
- 230000034994 death Effects 0.000 claims 1
- 231100000517 death Toxicity 0.000 claims 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 231100000080 dermatitis contact Toxicity 0.000 claims 1
- 231100000595 drug-induced hepatitis Toxicity 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000003104 endogenous depression Diseases 0.000 claims 1
- 229940030275 epigallocatechin gallate Drugs 0.000 claims 1
- 210000002919 epithelial cells Anatomy 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 201000002406 genetic disease Diseases 0.000 claims 1
- 230000002757 inflammatory Effects 0.000 claims 1
- 230000000968 intestinal Effects 0.000 claims 1
- 201000004044 liver cirrhosis Diseases 0.000 claims 1
- 201000003895 major depressive disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000008895 mood disease Diseases 0.000 claims 1
- 230000002969 morbid Effects 0.000 claims 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 201000006487 neurotic disease Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000006518 pelvic inflammatory disease Diseases 0.000 claims 1
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 201000009916 postpartum depression Diseases 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 230000000306 recurrent Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000009031 substance-related disease Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 201000006704 ulcerative colitis Diseases 0.000 claims 1
- 201000001862 viral hepatitis Diseases 0.000 claims 1
- 230000003612 virological Effects 0.000 claims 1
Claims (27)
炎症性疾病または疾患が、全身性ループス、炎症性腸疾患、アレルギー性鼻炎、接触性皮膚炎、喘息、自己免疫性肝炎、および骨盤内炎症性疾患から成る群から選択され；
うつ病性疾患が、がん、パーキンソン病、およびＨＩＶから成る群から選択される１以上の疾病または疾患の治療を受けるかまたは受けている対象に生じる併存うつ病であり；
肝臓疾病または疾患が、アルコール性肝臓疾患、非アルコール性脂肪肝疾患、ウイルス性または非ウイルス性肝炎、肝臓がん、酸化肝臓疾患、薬剤性の肝臓損傷、胆汁鬱滞、および肝硬変から成る群から選択され；
がんが、肝臓がん、結腸がん、直腸がん、胃がん、食道がん、および腺がんから成る群から選択され；
関節疾病または疾患が、関節炎または変形性関節症である、
請求項２５に記載の組成物。 Psychiatric or psychiatric disorders are anxiety disorder, schizophrenia, major depressive disorder, major depression, clinical depression, dysthymic disorder, anxiety depression, atypical depression, melancholic depression, tension Morbid depression, situational depression, reactive depression, elderly depression, seasonal affective disorder (SAD), minor depression, postpartum depression, inflammatory depression, elderly depression, Consisting of brief recurrent depression, mild depression, treatment-resistant depression (TRD), comorbid depression, Parkinson's disease depression, HIV-related depression, multiple infarct dementia, and bipolar disorder Selected from the group;
The inflammatory disease or disorder is selected from the group consisting of systemic lupus, inflammatory bowel disease, allergic rhinitis, contact dermatitis, asthma, autoimmune hepatitis, and pelvic inflammatory disease;
The depressive disorder is a comorbid depression that occurs in a subject who is receiving or undergoing treatment for one or more diseases or disorders selected from the group consisting of cancer, Parkinson's disease, and HIV;
Liver disease or disorder selected from the group consisting of alcoholic liver disease, non-alcoholic fatty liver disease, viral or non-viral hepatitis, liver cancer, oxidized liver disease, drug-induced liver injury, cholestasis, and cirrhosis Is;
The cancer is selected from the group consisting of liver cancer, colon cancer, rectal cancer, stomach cancer, esophageal cancer, and adenocarcinoma;
The joint disease or disorder is arthritis or osteoarthritis,
26. The composition of claim 25.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261715138P | 2012-10-17 | 2012-10-17 | |
| US61/715,138 | 2012-10-17 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015537091A Division JP5877935B2 (en) | 2012-10-17 | 2013-10-16 | Composition comprising S-adenosylmethionine and gallic acid ester |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016074725A JP2016074725A (en) | 2016-05-12 |
| JP2016074725A5 true JP2016074725A5 (en) | 2016-11-24 |
| JP6280535B2 JP6280535B2 (en) | 2018-02-14 |
Family
ID=50487370
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015537091A Expired - Fee Related JP5877935B2 (en) | 2012-10-17 | 2013-10-16 | Composition comprising S-adenosylmethionine and gallic acid ester |
| JP2015238622A Active JP6280535B2 (en) | 2012-10-17 | 2015-12-07 | Composition comprising S-adenosylmethionine and gallic acid ester |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015537091A Expired - Fee Related JP5877935B2 (en) | 2012-10-17 | 2013-10-16 | Composition comprising S-adenosylmethionine and gallic acid ester |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US9801896B2 (en) |
| EP (2) | EP2949331A1 (en) |
| JP (2) | JP5877935B2 (en) |
| KR (2) | KR20160094451A (en) |
| CN (2) | CN106074589A (en) |
| AU (1) | AU2013332209B2 (en) |
| CA (1) | CA2888302C (en) |
| DK (1) | DK2753336T3 (en) |
| ES (1) | ES2540581T3 (en) |
| HK (2) | HK1199836A1 (en) |
| IL (1) | IL243585A0 (en) |
| IN (1) | IN2015DN04151A (en) |
| RU (2) | RU2016117290A (en) |
| SG (1) | SG11201503048TA (en) |
| WO (1) | WO2014059522A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2016117290A (en) * | 2012-10-17 | 2018-10-23 | Метилэйшн Сайенсис Интернэшнл Срл | COMPOSITIONS CONTAINING S-Adenosylmethionine and Gallic Acid Complex Ether |
| CN106714810A (en) * | 2014-04-14 | 2017-05-24 | 甲基化物科学国际有限公司 | Novel ademetionine formulations |
| RU2587331C1 (en) * | 2015-06-19 | 2016-06-20 | Общество с ограниченной ответственностью "Полигепазол" | Method of producing pharmaceutical composition ademetionine and dosage form thereof |
| CN105232515A (en) * | 2015-10-10 | 2016-01-13 | 齐齐哈尔医学院 | Application of ethyl gallate for preparing drugs for treating human colon carcinoma cell apoptosis |
| CN105476982A (en) * | 2016-02-02 | 2016-04-13 | 张干 | New application of gallic acid |
| KR102425328B1 (en) | 2016-05-03 | 2022-07-25 | 헤래우스 쿼츠 노쓰 아메리카 엘엘씨 | Elongation method and preform for producing an optical glass component |
| CN108853085A (en) * | 2017-05-15 | 2018-11-23 | 苏州凯祥生物科技有限公司 | Catechin and epicatechin class compound are used to raise the purposes of MicroRNA-126 expression |
| CN111265509A (en) * | 2020-02-19 | 2020-06-12 | 齐鲁工业大学 | Application of gallic acid derivative in preventing and treating atherosclerosis diseases |
| CN114931571A (en) * | 2022-03-30 | 2022-08-23 | 上海中医药大学附属曙光医院 | Application of gallic acid methyl ester in preparation of osteoarthritis treatment medicine |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE37913B1 (en) | 1972-08-02 | 1977-11-09 | Bioresearch Sas | Salt of s-adenosyl-l-methionine |
| IT1173992B (en) | 1984-05-16 | 1987-06-24 | Bioresearch Spa | STABLE SALTS OF SULPHO-ADENOSYL-METHIONINE (SAME) PARTICULARLY SUITABLE FOR ORAL PHARMACEUTICAL USE |
| FR2623396B1 (en) | 1987-11-25 | 1990-03-30 | Sanofi Sa | USE OF ADEMETIONINE AGAINST AGING SKIN |
| GB8900812D0 (en) | 1989-01-14 | 1989-03-08 | Univ Manchester | Pharmaceutical method and compositions |
| JPH05271067A (en) | 1992-03-24 | 1993-10-19 | Takeda Chem Ind Ltd | Fibrosis-suppressing agent |
| RU2018314C1 (en) | 1993-07-15 | 1994-08-30 | Приморское научное медико-техническое общество | Agent for treatment of eczema |
| DE19631085A1 (en) | 1996-08-01 | 1998-02-05 | Basf Ag | Use of (meth) acrylic acid-maleic acid copolymers to improve the permeability of the mucosa |
| US6180666B1 (en) | 1997-09-05 | 2001-01-30 | Anmax, Inc. | Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds |
| US5962522A (en) * | 1997-09-05 | 1999-10-05 | Avmax, Inc. | Propyl gallate to increase bioavailability of orally administered pharmaceutical compounds |
| US7906153B2 (en) | 1998-04-08 | 2011-03-15 | Theta Biomedical Consulting & Development Co., Inc. | Anti-inflammatory compositions for treating multiple sclerosis |
| FI113942B (en) | 2000-08-18 | 2004-07-15 | Control Ox Oy | Use of Vegetable Phenolic Compounds in the Manufacture of Pharmaceutical Preparation Useful in the Treatment and Prevention of Chlamydia Infection, Nutritional Benefits or Composition for Addition to Such Foods |
| GB2368792A (en) | 2000-10-06 | 2002-05-15 | Roger Randal Charles New | Absorption enhancers |
| US6759395B2 (en) | 2000-12-18 | 2004-07-06 | Orchid Chemicals & Pharmaceuticals, Ltd. | Soft-gelatin capsule comprising S-adenosylmethionine and a method for producing the same |
| GB0308732D0 (en) | 2003-04-15 | 2003-05-21 | Axcess Ltd | Absorption enhancers |
| GB0308734D0 (en) | 2003-04-15 | 2003-05-21 | Axcess Ltd | Uptake of macromolecules |
| US8263574B2 (en) | 2004-09-29 | 2012-09-11 | James L. Schaller, P.A. | Topical formulations for the treatment of depression with S adenosyl methionine |
| GB0603252D0 (en) | 2006-02-17 | 2006-03-29 | Axcess Ltd | Dissolution aids for oral peptide delivery |
| US20070265211A1 (en) * | 2006-05-12 | 2007-11-15 | Matthias Rath | Novel composition and method effective in inhibiting the atherogenic process |
| BRPI0720982A2 (en) | 2006-12-28 | 2014-03-11 | Microbiotech Inc | PHARMACEUTICAL COMPOSITIONS OF ALKYL GALATE |
| US20090197824A1 (en) | 2008-01-31 | 2009-08-06 | Methylation Sciences International Srl | Extended Release Pharmaceutical Formulations of S-Adenosylmethionine |
| US20090088404A1 (en) | 2007-01-31 | 2009-04-02 | Methylation Sciences International Srl | Extended Release Pharmaceutical Formulations of S-Adenosylmethionine |
| AU2008210327B2 (en) * | 2007-01-31 | 2011-06-16 | Methylation Sciences International Srl | Extended release pharmaceutical formulations of S-adenosylmethionine |
| CN101012336A (en) * | 2007-01-31 | 2007-08-08 | 浙江大学 | High-strength degradable cereal protein plastics containing plant oil and preparing method thereof |
| US8542832B2 (en) | 2008-08-01 | 2013-09-24 | Nikolajs VOLKOVS | System and method for the calculation of a polynomial-based hash function and the erindale-plus hashing algorithm |
| WO2012012902A1 (en) | 2010-07-28 | 2012-02-02 | Msi Methylation Sciences Inc. | S-adenosylmethionine formulations with enhanced bioavailability |
| US20110027342A1 (en) * | 2009-07-28 | 2011-02-03 | Msi Methylation Sciences, Inc. | S-adenosylmethionine formulations with enhanced bioavailability |
| US8329208B2 (en) | 2009-07-28 | 2012-12-11 | Methylation Sciences International Srl | Pharmacokinetics of S-adenosylmethionine formulations |
| US20130004563A1 (en) | 2011-06-07 | 2013-01-03 | Shah Syed | Multiparticulate s-adenosylmethionine compositions and related methods |
| RU2016117290A (en) | 2012-10-17 | 2018-10-23 | Метилэйшн Сайенсис Интернэшнл Срл | COMPOSITIONS CONTAINING S-Adenosylmethionine and Gallic Acid Complex Ether |
-
2013
- 2013-10-16 RU RU2016117290A patent/RU2016117290A/en not_active Application Discontinuation
- 2013-10-16 WO PCT/CA2013/000876 patent/WO2014059522A1/en active Application Filing
- 2013-10-16 KR KR1020167020590A patent/KR20160094451A/en not_active Application Discontinuation
- 2013-10-16 EP EP15162054.9A patent/EP2949331A1/en not_active Withdrawn
- 2013-10-16 CN CN201610230503.7A patent/CN106074589A/en active Pending
- 2013-10-16 JP JP2015537091A patent/JP5877935B2/en not_active Expired - Fee Related
- 2013-10-16 DK DK13834351.2T patent/DK2753336T3/en active
- 2013-10-16 CA CA2888302A patent/CA2888302C/en active Active
- 2013-10-16 AU AU2013332209A patent/AU2013332209B2/en not_active Ceased
- 2013-10-16 EP EP20130834351 patent/EP2753336B1/en active Active
- 2013-10-16 CN CN201380054342.5A patent/CN104884067B/en active Active
- 2013-10-16 ES ES13834351.2T patent/ES2540581T3/en active Active
- 2013-10-16 IN IN4151DEN2015 patent/IN2015DN04151A/en unknown
- 2013-10-16 KR KR1020157012788A patent/KR101748053B1/en active IP Right Grant
- 2013-10-16 SG SG11201503048TA patent/SG11201503048TA/en unknown
- 2013-10-16 US US14/436,418 patent/US9801896B2/en active Active
- 2013-10-16 RU RU2015118235/15A patent/RU2586300C1/en active
-
2014
- 2014-04-07 US US14/247,061 patent/US8975238B2/en active Active
-
2015
- 2015-01-14 HK HK15100380.1A patent/HK1199836A1/en not_active IP Right Cessation
- 2015-02-23 US US14/628,623 patent/US9925208B2/en active Active
- 2015-12-07 JP JP2015238622A patent/JP6280535B2/en active Active
-
2016
- 2016-01-12 IL IL243585A patent/IL243585A0/en unknown
- 2016-05-24 HK HK16105924.2A patent/HK1217909A1/en unknown
-
2018
- 2018-02-16 US US15/932,359 patent/US20190022119A1/en not_active Abandoned
-
2019
- 2019-12-26 US US16/727,610 patent/US20200129537A1/en not_active Abandoned
-
2022
- 2022-03-07 US US17/688,679 patent/US20220193107A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016074725A5 (en) | ||
| US11020375B2 (en) | Edaravone dosage form | |
| JP6280535B2 (en) | Composition comprising S-adenosylmethionine and gallic acid ester | |
| JP2013521310A5 (en) | ||
| WO2009091538A8 (en) | Pharmaceutical composition comprising epa and dha for treating hypertriglyceridemia and hypercholesterolemia | |
| ES2384701T1 (en) | Use of DHA, EPA or EPA derived from DHA for the treatment of a pathology associated with oxidative cell damage | |
| WO2014179325A1 (en) | Omega-3 fatty acid formulations for use as pharmaceutical treatment | |
| MX2012005677A (en) | Parenteral formulations of gemcitabine derivatives. | |
| WO2009154230A1 (en) | Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis | |
| JP2010523708A5 (en) | ||
| JP2003508484A5 (en) | ||
| JP2018533618A (en) | Composition comprising urolitin compound | |
| JP2023065454A (en) | Compositions Comprising 15-Oxo-EPA or 15-Oxo-DGLA and Methods of Making and Using The Same | |
| IL250271B2 (en) | Mixture of fatty acids and palmitoylethanolamide for use in the treatment of inflammatory and allergic pathologies | |
| JP2017523230A5 (en) | ||
| US9700535B2 (en) | Oral pharmaceutical composition of isotretinoin | |
| WO2018092765A1 (en) | Nasally administered medical composition | |
| 中林圭介 | Evaluation of the association between sleep apnea and polyunsaturated fatty acids profiles in patients after percutaneous coronary intervention | |
| WO2016161683A1 (en) | Statin pharmaceutical composition, and capsule formulation and preparation method thereof | |
| GB2624353A (en) | Novel Omega 3 carrier preparations for inhalation drug delivery for treating lung inflammation | |
| JP2014070027A (en) | Therapeutic or preventive agent for meibomian gland dysfunction or meibomian gland concretion | |
| WO2017193563A1 (en) | Composition, and application and pharmaceutical preparation thereof | |
| RU2003108860A (en) | Thienopyrimidines | |
| RU2021108388A (en) | IRON-CONTAINING COMPOSITION AND ITS APPLICATION | |
| JP2019520370A (en) | Pharmaceutical composition comprising benzydamine |